Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Plasma biomarkers in a placebo-controlled trial comparing tDCS and escitalopram efficacy in major depression

Full text
Author(s):
Brunoni, Andre R. [1, 2, 3, 4, 5] ; Padberg, Frank [4] ; Marciano Vieira, Erica Leandro [6] ; Teixeira, Antonio Lucio [6, 7] ; Carvalho, Andre F. [8, 9] ; Lotufo, Paulo Andrade [1] ; Gattaz, Wagner F. [2, 3] ; Bensenor, Isabela Martins [1]
Total Authors: 8
Affiliation:
[1] Univ Sao Paulo, Univ Hosp, Sao Paulo - Brazil
[2] Univ Sao Paulo, Med Sch, Dept & Inst Psychiat, Lab Neurosci LIM27, Sao Paulo - Brazil
[3] Univ Sao Paulo, Med Sch, Dept & Inst Psychiat, Natl Inst Biomarkers Neuropsychiat INBioN, Sao Paulo - Brazil
[4] LMU, Univ Hosp, Dept Psychiat & Psychotherapy, Munich - Germany
[5] Univ Sao Paulo, Med Sch, Dept & Inst Psychiat, SIN, Sao Paulo - Brazil
[6] Univ Fed Minas Gerais, Interdisciplinary Lab Med Invest, Belo Horizonte, MG - Brazil
[7] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Psychiat & Behav Sci, Neuropsychiat Program, Houston, TX 77030 - USA
[8] Univ Toronto, Fac Med, Dept Psychiat, Toronto, ON - Canada
[9] CAMH, Toronto, ON M6J 1H4 - Canada
Total Affiliations: 9
Document type: Journal article
Source: PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY; v. 86, p. 211-217, AUG 30 2018.
Web of Science Citations: 8
Abstract

Background: Transcranial direct current stimulation (tDCS) holds promise as a therapeutic intervention for major depressive disorder (MDD). A more precise understanding of its underlying mechanisms may aid in the identification of subsets of patients responsive to tDCS within the context of precision psychiatry. Objective: In this ancillary investigation of the Escitalopram vs. Electrical Current Therapy for Treating Depression Clinical Study (ELECT-TDCS), we investigated whether plasma levels of several cytokines and neurotrophic factors associated with major depression or antidepressant response predicted tDCS effects. Methods: We examined, in 236 patients at 3 timepoints during a 10-week treatment course, plasma levels of nerve growth factor (NGF), brain-derived (BDNF), glial-cell line derived neurotrophic factor (GDNF), the interleukins (IL) IL-1 beta, IL-6, IL-8, IL-10, IL-12p70, IL-18, IL-33, tumor necrosis factor-alpha (TNF-alpha), and its soluble receptors sTNFrl and sTNFr2. General linear models and mixed-models analyses of variance were used to respectively assess whether plasma levels of these molecules (1) predicted tDCS antidepressant improvement and (2) changed over time. Results: After correction for multiple comparisons (false discovery rate method), NGF baseline levels predicted early depression improvement for tDCS vs. escitalopram, whilst other biomarkers did not significantly predict treatment improvement. The levels of IL12p70, IL10, IL-1 beta, IL-8 and sTNFr1 decreased over time, regardless of allocation group and clinical response. Conclusion: In general, peripheral biomarkers were not associated with the outcome. The post-hoc finding of baseline NGF levels predicting early depression improvement for tDCS should be explored in further studies. (AU)

FAPESP's process: 12/20911-5 - Escitalopram and transcranial direct current stimulation in major depressive disorder: a double blind, placebo-controlled, randomized, non-inferiority trial
Grantee:Andre Russowsky Brunoni
Support Opportunities: Research Grants - Young Investigators Grants